Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

USP Establishes Collaborative Research Agreement With Health Canada

By Pharmaceutical Processing | January 11, 2005

ROCKVILLE, MD (January 10, 2005) — The U.S. Pharmacopeia (USP) has announced a collaborative research agreement with Health Canada’s Health Products and Food Branch Inspectorate. The agreement became effective on September 7, 2004, and will remain in effect until March 2007. USP provides authoritative drug standards in the United States Pharmacopeia (USP) and National Formulary (NF) and official USP Reference Standards that are recognized worldwide.

Ronald G. Manning, Ph.D., USP’s vice president of monograph and reference standards development, and L. Valentin Feyns, Ph.D., a scientific fellow at USP, visited the Health Canada laboratories near Montreal after the finalization of the agreement to discuss its pending implementation. “We view the agreement with Health Canada as a significant step towards providing high quality standards for medicines produced globally,” said Dr. Manning.

Health Canada laboratories will assist in the testing and characterization of candidate (proposed) reference standards as part of the USP Reference Standards Development Process. Results of the testing will be included in the reports submitted to USP’s Reference Standards Committee for final approval. Although Canadian experts have been involved in the Reference Standards program almost from its inception, (and one Health Canada expert is currently a member of the USP Reference Standards Committee) this collaborative agreement marks the first time Health Canada has been formally involved in one of the most important programs at USP.

Diane C. Gorman, Assistant Deputy Minister at Health Canada commented, “I am pleased to see the long-standing collaboration between our scientists formalized with this agreement. This project will help to ensure the availability of USP Reference Standards used for testing the quality and safety of drugs in Canada, the U.S. and throughout the world.”

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE